Skip to main content

Table 1 Summary of intestinal Behçet’s disease patients with myelodysplastic syndrome associated with secondary pulmonary alveolar proteinosis

From: Intestinal Behçet’s disease complicated by myelodysplastic syndrome and secondary pulmonary alveolar proteinosis: a case report

Author/year (reference) Age/sex MDS type BD symptoms Chromosomal abnormalities/HLA Respiratory symptoms HRCT findings (GGO pattern) Treatment before MDS onset (duration, years) Outcome
Handa/2014 [8] 49/F RA G, I, O, S Trisomy 8/HLA-B51- None Diffuse Cyclosporine A, Prednisolone, Sulfasalazine, TNF-inhibitor (14 years) Dead
Handa/2014 [8] 33/M RA I, O, S Trisomy 8/HLA-B51 - Cough Diffuse Azathioprine, Prednisolone, Sulfasalazine, TNF inhibitor (5 years) Dead
Present case/2021 58/F RA G, I, O, S Trisomy 8, Trisomy 9, X, i(X)(q10)/HLA-B51+ Cough
Diffuse Colchicine, Methalazine, Prednisolone, TNF inhibitor (3 years) alive
  1. BD, Behçet’s disease; G, genital ulcer; GGO, ground-glass opacity; HLA, human leukocyte antigen; HRCT, high-resolution computed tomography; I, intestinal lesions; MDS, myelodysplastic syndrome; O, oral ulcer; RA, Refractory anemia; S, skin lesion; TNF, tumor necrosis factor